R. Michael Carruthers - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: EWTX
Reported as of: 12 Aug 2025
Net transaction value: -$19,124
SEC form: 4
Accepted by SEC: 14 Aug 2025, 19:43:04 UTC
Prior SEC filing: 24 Jul 2025
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers

Key filing fact

R. Michael Carruthers filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2025.

Key facts

This page summarizes R. Michael Carruthers's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 19:43.

Change

Previous filing in this sequence was filed on 24 Jul 2025.
Current net transaction value: -$19,124.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644467 Primary reporting owner

Carruthers R Michael

Relationship: Chief Financial Officer
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: /s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EWTX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +5,781
Change %: +7.1%
Price: $0.000000
Shares after: 87,590
Date: 12 Aug 2025
Ownership: Direct
Footnotes: F1

EWTX transaction

Common Stock

Sale

Transaction value: $19,124
Shares: -1,428
Change %: -1.6%
Price: $13.39
Shares after: 86,162
Date: 12 Aug 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -5,781
Change %: -25%
Price: $0.000000
Shares after: 17,344
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,781
Exercise price: $0.000000
Footnotes: F4

EWTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +26,875
Change %
Price: $0.000000
Shares after: 26,875
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,875
Exercise price: $0.000000
Footnotes: F5

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +161,250
Change %
Price: $0.000000
Shares after: 161,250
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 161,250
Exercise price: $13.39
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Includes 795 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

Footnote F2

Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

Footnote F3

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

Footnote F5

Footnote F6

1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.